Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for preventing or treating neuronal damage and neurological diseases

Inactive Publication Date: 2012-03-01
MOON J
View PDF4 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0019]The at least one compound selected from the group consisting of the compound represented by Formula 1, the compound represented by Formula 2, and an available salt thereof used as an active ingredient repairs damaged nerve tissues quickly to effectively prevent or treat neuronal damage and neurological diseases, such as neuropathy, neuropathic pain or cerebropathy.

Problems solved by technology

However, the method requires injection of protein or a protein factor into the brain and is not applicable to general practices.
However, in many clinical situations, traumatic or disease-induced neuron damage results in limited repair and, in general, substantial delay.
However, typically, the allopathic agents are not effective and if pain is strong or lasts long, neuron blocking techniques are actively used.
Currently, a prescription for the herpes zoster treatment mainly includes use of an antivirus agent and an anti-inflammatory analgesic drug, and is not effective for repairing damaged nerve tissue, which is an etiological factor of herpes zoster and post-herpetic neuralgia.
Thus, it is impossible to effectively control pain.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for preventing or treating neuronal damage and neurological diseases
  • Pharmaceutical composition for preventing or treating neuronal damage and neurological diseases
  • Pharmaceutical composition for preventing or treating neuronal damage and neurological diseases

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation of H-Z Cream

[0052]0.7 g of potassium hydroxide and 10 mL of glycerin were dissolved in 75 mL of purified water in a 200 mL beaker and then the solution was heated at a temperature of 80 to 85° C. This solution was added to a liquid stearic acid prepared by completely melting 15 g of stearic acid in a 250 mL beaker in a water bath at a temperature of 80 to 85° C. and stirred and cooled to room temperature, thereby preparing a vanishing cream.

[0053]100.7 g of the prepared vanishing cream was added to 229.0 g of aloe vera gel and the mixture was sufficiently mixed. Then, 16.03 g of Oronia Soybean Lecithin (supplier: Deraco Natural Source Company LTD.) as a phospholipid or sphingosine derivative, 1.60 g of alpha-tocopherol, and 0.50 g of propyl benzoate were each added thereto in small portions while stirring, thereby preparing a light yellowish cream. The resultant composition included 1.7 wt % of phospholipid or a sphingosine derivative.

example 2

Preparation of H-Z Cream

[0054]4.00 g of Tween #80 was added to 200.0 g of aloe vera gel and the mixture was sufficiently mixed. Then, 20.00 g of Oronia Soybean Lecithin (supplier: Deraco Natural Source Company LTD.), 2.00 g of alpha-tocopherol, and 0.30 g of propyl benzoate were each added thereto in small portions while stirring, thereby preparing a light yellowish cream. The resultant composition included 3.24 wt % of phospholipid or a sphingosine derivative.

example 3

Preparation of H-Z Cream

[0055]14.00 g of Tween #80 was added to 127.0 g of aloe vera gel and the mixture was sufficiently mixed. Then, 70.00 g of GL-90E (supplier: GoshenBiotech) as phospholipid or a sphingosine derivative, 7.00 g of alpha-tocopherol, and 0.30 g of propyl benzoate were each added thereto in small portions while stirring, thereby preparing a light yellowish cream. The resultant composition included 29.1 wt % phospholipid or a sphingosine derivative.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Volumeaaaaaaaaaa
Timeaaaaaaaaaa
Timeaaaaaaaaaa
Login to View More

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating neuronal damage and neurological diseases, and more particularly, to a pharmaceutical composition for preventing or treating neuronal damage and neurological diseases containing, as active ingredients, any one or two or more compounds selected from a group consisting of the compound of chemical formula 1, the compound of chemical formula 2, and the acceptable salts thereof.The pharmaceutical composition repairs nerve tissue damaged by herpes zoster to reduce the acute pain caused by herpes zoster, prevents postherpetic neuralgia, and enables a fundamental treatment through the recovery of nerve tissue in the postherpetic neuralgia. Further, the pharmaceutical composition can be effectively used for neuronal damage, including sciatic nerve crushing damage or the like, in a neuropathy including diabetic neuropathy or the like and for neuropathic pain, as well as for a variety of diseases caused by nerve tissue damage, such as brain diseases including strokes or the like.

Description

TECHNICAL FIELD[0001]The present invention relates to a pharmaceutical composition that effectively treats neuronal damage, such as damage of peripheral nerves or damage of central nerves, and neurological diseases, such as neuropathy, neuropathic pain or cerebropathy, by repairing damaged nerve tissues.BACKGROUND ART[0002]Various neurological diseases, such as Parkinson's disease, Alzheimer's disease, Huntington's disease, spino cerebellar degeneration, amyotrophic lateral sclerosis, polyneuropathy, spinal cord damage, cerebrovascular disorder, or the like, develop due to degeneration, reduction, cell death, or damage or exclusion of brain or peripheral neurons caused by, for example, environmental or hereditary factors. Accordingly, in treating these neurological diseases, it is important to either compensate for a neuron delivery material that is removed by damage of neurons or regenerate neurons. To regenerate neurons, an undifferentiated neuron stem cell, an embryonic stem cell...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/685C07F9/655C07C215/24C07F9/09C07H15/04A61P25/08A61K31/683A61K31/133A61P25/00A61P25/04A61P25/28A61P25/16C07F9/10A61K31/7032
CPCA61K9/0014A61K9/107A61K36/886A61K31/685A61K31/688A61K31/661A61P25/00A61P25/02A61P25/04A61P25/08A61P25/14A61P25/16A61P25/28A61P29/00A61P31/22A61P35/00A61P9/00A61P9/10A61P3/10
Inventor JUNG, JAE-HOONMOON, HYUNG-RYONG
Owner MOON J
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products